EconRx

Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode …

Capping patient out-of-pocket costs for insulin has been a popular move for legislators, most recently by the US House. On this episode we weigh the Pros, Cons, and viral reactions to this move inclu…

After explaining a HORRENDOUS mistake made recently by the NABP and the oversight of NAPLEX testing that affected one of our own, we decided it's high time we dove into the controversy around the use…

On this episode we were blessed to have on Kyle McCormick, owner/operator of Blueberry Pharmacy, to explain his unique (but traditionally familiar) business model. Blueberry operates on a cost-plus m…

The Twittersphere recently noticed that quoted savings on Amazon Pharmacy are a little bit unrealistic. On this episode we break down how a pharmacy's "Usual & Customary" price SHOULD be calculated, …

The COVID-19 pandemic highlighted many weaknesses in the US Drug Supply Chain's dependence on foreign production (similar to toilet paper, masks, etc.). The Biden White House recently announced plans…

After a brief hiatus we are back in the studio! Everyone has important life updates to share, Aaron has some interesting learning points about Medicaid rebates, Ryan explains DIR fees, and we check b…

Since we have had guests on for the last few episodes, we wanted to take some time to cover some recent topics that have come up in the first quarter of 2021. Chosen topics:

Aaron - COVID vaccine hes…

We are beyond excited to welcome AJ Rivosecchi, PharmD onto the podcast to talk about Kit Check. A company that started as a tool for managing hospital medication inventory is growing to address drug…

Ever been to an independent pharmacy? One with a soda fountain and ice cream bar? The level of service provided is a far cry more personal than the usual retail-pharmacy experience. Don't believe us?…

On this episode we are joined by the one and only Mike Corvino of the @CorConsultRx podcast to talk about recent attacks on the 340B program. We outline, with a provider's perspective, how the 340B p…

2020 IS OVER!!! Well, almost anyway. Before we end the weirdest year ever, we wanted to give you one more episode. We discussed a bunch of random stuff like the supreme court and vaccine approvals (Y…

Amazon is officially entering the mail order pharmacy space. Is this going to be a huge market-up-ending disruption like every other space the online retail giant enters? Hard to say at this point, b…

On this episode we were able to fit in two topics! First, we gave an update of the status of COVID-19 vaccines following some exciting news from Pfizer this week. We then began to discuss challenges …

On Oct 6, 2020 JAMA published an article by R. Sachs (link below) that explains the impossible position different pieces of Federal legislation have created for State Medicaid programs. In this episo…

On September 13th the White House published the "Executive Order on Lowering Drug Prices by Putting America First." EconRx breaks down the who, what, where, why, and HOW of this latest attempt to add…

Ever wonder how private health insurance became so common in the US? Or why it's most commonly given as a benefit from an employer? We break down the history of how this came to be and what that mean…

This week the Trio break down GoodRx and the recent news that the prescription discount company wants to go public. How does a company that saves patients money...make money? The answer is a little f…

Did you know Medicare is the single biggest provider of health insurance in the US? Now you do. You're welcome. Josh and Aaron give an overview of this enormous government program and discuss its ups…

THE BOYS ARE BACK IN TOWN...or at least able to record in person for a change. On this episode we are joined by Mike Corvino of CorConsult Rx to talk about telehealth changes, billing, and its potent…